Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration sur l'oranger

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study

Identifieur interne : 002092 ( Main/Exploration ); précédent : 002091; suivant : 002093

Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study

Auteurs : Julius Oben [Cameroun] ; Ebangha Enonchong [Cameroun] ; Shil Kothari [États-Unis] ; Walter Chambliss [États-Unis] ; Robert Garrison [États-Unis] ; Deanne Dolnick [États-Unis]

Source :

RBID : PMC:2409365

English descriptors

Abstract

Background

The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP 06-1, on cardiovascular protective properties in overweight and normal weight adults diagnosed with osteoarthritis of the knee.

Methods

An 8-week, placebo-controlled, randomized, double-blind study was conducted with four groups, comparing the effects of NP 06-1 to placebo in overweight and normal weight subjects diagnosed with primary osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts; Phellodendron amurense bark and Citrus sinensis peel) or matching placebo was given in a dose of two capsules (370 mg each) twice daily. The outcome measures reported are lipid levels, weight, BMI, blood pressure and fasting glucose. Analyses of variance were used to compare changes of physiological measures over the trial period and between groups.

Results

Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. NP 06-1 administration was associated with a general improvement in lipid levels. Both the overweight and normal weight treatment groups had significant reductions in triglycerides and LDL-cholesterol, as well as a significant increase in HDL-cholesterol compared to their respective control groups.

Overall there were decreases in blood pressure in both overweight and normal weight treatment groups compared to respective placebo groups. There was also a significant decrease in fasting glucose levels in the overweight treatment group compared to the start of the study and to the overweight placebo group. There was no change in fasting blood sugar for the normal weight groups.

Both overweight and normal weight treatment groups lost a significant amount of weight compared to their respective placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks, which was associated with a significant loss in BMI over time.

Conclusion

In this pilot study NP 06-1 had a beneficial effect on cardiovascular risk factors; namely lipid levels, blood pressure and fasting glucose levels. Administration of NP 06-1 was also associated with weight loss.


Url:
DOI: 10.1186/1475-2891-7-16
PubMed: 18492265
PubMed Central: 2409365


Affiliations:

Links toward previous steps (curation, corpus...)

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">
<italic>Phellodendron </italic>
and
<italic>Citrus </italic>
extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study</title>
<author>
<name sortKey="Oben, Julius" sort="Oben, Julius" uniqKey="Oben J" first="Julius" last="Oben">Julius Oben</name>
<affiliation wicri:level="1">
<nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff>
<country xml:lang="fr">Cameroun</country>
<wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea>
<wicri:noRegion>University of Yaounde I</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Enonchong, Ebangha" sort="Enonchong, Ebangha" uniqKey="Enonchong E" first="Ebangha" last="Enonchong">Ebangha Enonchong</name>
<affiliation wicri:level="1">
<nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff>
<country xml:lang="fr">Cameroun</country>
<wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea>
<wicri:noRegion>University of Yaounde I</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Kothari, Shil" sort="Kothari, Shil" uniqKey="Kothari S" first="Shil" last="Kothari">Shil Kothari</name>
<affiliation wicri:level="1">
<nlm:aff id="I2">Gateway Health Alliances, Inc, 4769 Mangels Blvd, Fairfield, CA, 94534, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gateway Health Alliances, Inc, 4769 Mangels Blvd, Fairfield, CA, 94534</wicri:regionArea>
<wicri:noRegion>94534</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Chambliss, Walter" sort="Chambliss, Walter" uniqKey="Chambliss W" first="Walter" last="Chambliss">Walter Chambliss</name>
<affiliation wicri:level="1">
<nlm:aff id="I3">University of Mississippi, University, MS, 38677, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Mississippi, University, MS, 38677</wicri:regionArea>
<wicri:noRegion>38677</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Garrison, Robert" sort="Garrison, Robert" uniqKey="Garrison R" first="Robert" last="Garrison">Robert Garrison</name>
<affiliation wicri:level="1">
<nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907</wicri:regionArea>
<wicri:noRegion>93907</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dolnick, Deanne" sort="Dolnick, Deanne" uniqKey="Dolnick D" first="Deanne" last="Dolnick">Deanne Dolnick</name>
<affiliation wicri:level="1">
<nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907</wicri:regionArea>
<wicri:noRegion>93907</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">18492265</idno>
<idno type="pmc">2409365</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409365</idno>
<idno type="RBID">PMC:2409365</idno>
<idno type="doi">10.1186/1475-2891-7-16</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000988</idno>
<idno type="wicri:Area/Pmc/Curation">000987</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001093</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000A58</idno>
<idno type="wicri:Area/PubMed/Curation">000A58</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A58</idno>
<idno type="wicri:Area/Ncbi/Merge">000833</idno>
<idno type="wicri:Area/Ncbi/Curation">000833</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000833</idno>
<idno type="wicri:Area/Main/Merge">002154</idno>
<idno type="wicri:Area/Main/Curation">002092</idno>
<idno type="wicri:Area/Main/Exploration">002092</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">
<italic>Phellodendron </italic>
and
<italic>Citrus </italic>
extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study</title>
<author>
<name sortKey="Oben, Julius" sort="Oben, Julius" uniqKey="Oben J" first="Julius" last="Oben">Julius Oben</name>
<affiliation wicri:level="1">
<nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff>
<country xml:lang="fr">Cameroun</country>
<wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea>
<wicri:noRegion>University of Yaounde I</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Enonchong, Ebangha" sort="Enonchong, Ebangha" uniqKey="Enonchong E" first="Ebangha" last="Enonchong">Ebangha Enonchong</name>
<affiliation wicri:level="1">
<nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff>
<country xml:lang="fr">Cameroun</country>
<wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea>
<wicri:noRegion>University of Yaounde I</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Kothari, Shil" sort="Kothari, Shil" uniqKey="Kothari S" first="Shil" last="Kothari">Shil Kothari</name>
<affiliation wicri:level="1">
<nlm:aff id="I2">Gateway Health Alliances, Inc, 4769 Mangels Blvd, Fairfield, CA, 94534, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gateway Health Alliances, Inc, 4769 Mangels Blvd, Fairfield, CA, 94534</wicri:regionArea>
<wicri:noRegion>94534</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Chambliss, Walter" sort="Chambliss, Walter" uniqKey="Chambliss W" first="Walter" last="Chambliss">Walter Chambliss</name>
<affiliation wicri:level="1">
<nlm:aff id="I3">University of Mississippi, University, MS, 38677, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Mississippi, University, MS, 38677</wicri:regionArea>
<wicri:noRegion>38677</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Garrison, Robert" sort="Garrison, Robert" uniqKey="Garrison R" first="Robert" last="Garrison">Robert Garrison</name>
<affiliation wicri:level="1">
<nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907</wicri:regionArea>
<wicri:noRegion>93907</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dolnick, Deanne" sort="Dolnick, Deanne" uniqKey="Dolnick D" first="Deanne" last="Dolnick">Deanne Dolnick</name>
<affiliation wicri:level="1">
<nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA, 93907</wicri:regionArea>
<wicri:noRegion>93907</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Nutrition Journal</title>
<idno type="eISSN">1475-2891</idno>
<imprint>
<date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Analysis of Variance</term>
<term>Blood Glucose (drug effects)</term>
<term>Blood Pressure (drug effects)</term>
<term>Body Mass Index</term>
<term>Cardiovascular Diseases (blood)</term>
<term>Cardiovascular Diseases (prevention & control)</term>
<term>Citrus (chemistry)</term>
<term>Dietary Supplements</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Lipid Metabolism (drug effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Osteoarthritis (blood)</term>
<term>Overweight</term>
<term>Phellodendron (chemistry)</term>
<term>Pilot Projects</term>
<term>Plant Extracts (pharmacology)</term>
<term>Treatment Outcome</term>
<term>Weight Loss (drug effects)</term>
<term>Weight Loss (physiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en">
<term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Cardiovascular Diseases</term>
<term>Osteoarthritis</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en">
<term>Citrus</term>
<term>Phellodendron</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Blood Pressure</term>
<term>Lipid Metabolism</term>
<term>Weight Loss</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Plant Extracts</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Weight Loss</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Analysis of Variance</term>
<term>Body Mass Index</term>
<term>Dietary Supplements</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Overweight</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Background</title>
<p>The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP 06-1, on cardiovascular protective properties in overweight and normal weight adults diagnosed with osteoarthritis of the knee.</p>
</sec>
<sec sec-type="methods">
<title>Methods</title>
<p>An 8-week, placebo-controlled, randomized, double-blind study was conducted with four groups, comparing the effects of NP 06-1 to placebo in overweight and normal weight subjects diagnosed with primary osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts;
<italic>Phellodendron amurense </italic>
bark and
<italic>Citrus sinensis </italic>
peel) or matching placebo was given in a dose of two capsules (370 mg each) twice daily. The outcome measures reported are lipid levels, weight, BMI, blood pressure and fasting glucose. Analyses of variance were used to compare changes of physiological measures over the trial period and between groups.</p>
</sec>
<sec>
<title>Results</title>
<p>Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. NP 06-1 administration was associated with a general improvement in lipid levels. Both the overweight and normal weight treatment groups had significant reductions in triglycerides and LDL-cholesterol, as well as a significant increase in HDL-cholesterol compared to their respective control groups.</p>
<p>Overall there were decreases in blood pressure in both overweight and normal weight treatment groups compared to respective placebo groups. There was also a significant decrease in fasting glucose levels in the overweight treatment group compared to the start of the study and to the overweight placebo group. There was no change in fasting blood sugar for the normal weight groups.</p>
<p>Both overweight and normal weight treatment groups lost a significant amount of weight compared to their respective placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks, which was associated with a significant loss in BMI over time.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>In this pilot study NP 06-1 had a beneficial effect on cardiovascular risk factors; namely lipid levels, blood pressure and fasting glucose levels. Administration of NP 06-1 was also associated with weight loss.</p>
</sec>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations>
<list>
<country>
<li>Cameroun</li>
<li>États-Unis</li>
</country>
</list>
<tree>
<country name="Cameroun">
<noRegion>
<name sortKey="Oben, Julius" sort="Oben, Julius" uniqKey="Oben J" first="Julius" last="Oben">Julius Oben</name>
</noRegion>
<name sortKey="Enonchong, Ebangha" sort="Enonchong, Ebangha" uniqKey="Enonchong E" first="Ebangha" last="Enonchong">Ebangha Enonchong</name>
</country>
<country name="États-Unis">
<noRegion>
<name sortKey="Kothari, Shil" sort="Kothari, Shil" uniqKey="Kothari S" first="Shil" last="Kothari">Shil Kothari</name>
</noRegion>
<name sortKey="Chambliss, Walter" sort="Chambliss, Walter" uniqKey="Chambliss W" first="Walter" last="Chambliss">Walter Chambliss</name>
<name sortKey="Dolnick, Deanne" sort="Dolnick, Deanne" uniqKey="Dolnick D" first="Deanne" last="Dolnick">Deanne Dolnick</name>
<name sortKey="Garrison, Robert" sort="Garrison, Robert" uniqKey="Garrison R" first="Robert" last="Garrison">Robert Garrison</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Bois/explor/OrangerV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002092 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002092 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Bois
   |area=    OrangerV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:2409365
   |texte=   Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18492265" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a OrangerV1
Wicri

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 17:11:04 2016. Site generation: Wed Mar 6 18:18:32 2024